NGR-hTNF

Phase 3Small molecule

AAGC Biologics S.p.A.

NGR-hTNF is one of 225 small molecule programs targeting Small Cell Lung Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

224

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CarcinomaActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

NecrosisActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Small Cell Lung CarcinomaPhase 2

Active, not recruiting

Malignant Pleural MesotheliomaPhase 3

Active, not recruiting

NecrosisPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

NGR-hTNF

AAGC Biologics S.p.A.

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 5

REGN2810

Regeneron

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Vidaza

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer3 trials

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00484432·37 enrolled

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Completed·AAGC Biologics S.p.A.·Phase 2·NCT01358071·119 enrolled

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Completed·AAGC Biologics S.p.A.·Phase 2·NCT03804866·14 enrolled

Malignant Pleural Mesothelioma2 trials

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Completed·AAGC Biologics S.p.A.·Phase 3·NCT01098266·400 enrolled

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00484276·57 enrolled

Advanced Solid Tumors1 trial

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

Completed·AAGC Biologics S.p.A.·Phase 1·NCT00419328·16 enrolled

Small Cell Lung Carcinoma1 trial

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00483509·28 enrolled

Advanced or Metastatic Solid Tumour1 trial

Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour

Completed·AAGC Biologics S.p.A.·Phase 1·NCT00878111·48 enrolled

8 more indications

Necrosis1 trial

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

Completed·AAndres J. M. Ferreri·Phase 2·NCT03536039·28 enrolled

Non-Small Cell Lung Cancer1 trial

NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00994097·121 enrolled

Colorectal Cancer1 trial

Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00483080·46 enrolled

Metastatic Colorectal Cancer1 trial

NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00675012·24 enrolled

Maintenance Treatment1 trial

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

Completed·AAGC Biologics S.p.A.·Phase 2·NCT01358084·137 enrolled

Solid Tumors1 trial

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

Completed·AAGC Biologics S.p.A.·Phase 1·NCT00305084·15 enrolled

Hepatocellular Carcinoma1 trial

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00484211·40 enrolled

Solid Tumor1 trial

Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

Completed·AAGC Biologics S.p.A.·Phase 1·NCT00483093·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for NGR-hTNF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NGR-hTNF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NGR-hTNF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AGC Biologics S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAGC Biologics S.p.A.

NGR-hTNF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer3 trials

Malignant Pleural Mesothelioma2 trials

Advanced Solid Tumors1 trial

Small Cell Lung Carcinoma1 trial

Advanced or Metastatic Solid Tumour1 trial

Necrosis1 trial

Non-Small Cell Lung Cancer1 trial

Colorectal Cancer1 trial

Metastatic Colorectal Cancer1 trial

Maintenance Treatment1 trial

Solid Tumors1 trial

Hepatocellular Carcinoma1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News